Replies to post #218477 on Biotech Values

[DewDiligence]

The short answer is yes. SNDX’s Entinostat is not from the same drug class as INCY’s Epacostat, despite the similarity of the names.

I don’t have any explanation for the day-to-day movements in SNDX’s share price.